Vita 34 AG
XETRA:V3V
Intrinsic Value
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. [ Read More ]
The intrinsic value of one V3V stock under the Base Case scenario is 5.67 EUR. Compared to the current market price of 4.66 EUR, Vita 34 AG is Undervalued by 18%.
Valuation Backtest
Vita 34 AG
Run backtest to discover the historical profit from buying and selling V3V stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vita 34 AG
Current Assets | 34.3m |
Cash & Short-Term Investments | 10.4m |
Receivables | 18.8m |
Other Current Assets | 5.1m |
Non-Current Assets | 114.7m |
Long-Term Investments | 1.5m |
PP&E | 36.4m |
Intangibles | 56.4m |
Other Non-Current Assets | 20.5m |
Current Liabilities | 50.6m |
Accounts Payable | 7.9m |
Other Current Liabilities | 42.7m |
Non-Current Liabilities | 86.3m |
Long-Term Debt | 11.9m |
Other Non-Current Liabilities | 74.4m |
Earnings Waterfall
Vita 34 AG
Revenue
|
74.9m
EUR
|
Cost of Revenue
|
-64.2m
EUR
|
Gross Profit
|
10.7m
EUR
|
Operating Expenses
|
-32.8m
EUR
|
Operating Income
|
-22.1m
EUR
|
Other Expenses
|
-2.8m
EUR
|
Net Income
|
-24.9m
EUR
|
Free Cash Flow Analysis
Vita 34 AG
What is Free Cash Flow?
V3V Profitability Score
Profitability Due Diligence
Vita 34 AG's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Vita 34 AG's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
V3V Solvency Score
Solvency Due Diligence
Vita 34 AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Vita 34 AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
V3V Price Targets Summary
Vita 34 AG
According to Wall Street analysts, the average 1-year price target for V3V is 5.56 EUR with a low forecast of 5.35 EUR and a high forecast of 5.88 EUR.
Shareholder Return
V3V Price
Vita 34 AG
Average Annual Return | -8.93% |
Standard Deviation of Annual Returns | 28.58% |
Max Drawdown | -77% |
Market Capitalization | 73.8m EUR |
Shares Outstanding | 16 170 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
Contact
IPO
Employees
Officers
The intrinsic value of one V3V stock under the Base Case scenario is 5.67 EUR.
Compared to the current market price of 4.66 EUR, Vita 34 AG is Undervalued by 18%.